BRPI0907624A2 - tratamento e prevenção de doenças cardíacas usando duas ou mais isoformas do fator de crescimento de hepatócito - Google Patents

tratamento e prevenção de doenças cardíacas usando duas ou mais isoformas do fator de crescimento de hepatócito

Info

Publication number
BRPI0907624A2
BRPI0907624A2 BRPI0907624A BRPI0907624A BRPI0907624A2 BR PI0907624 A2 BRPI0907624 A2 BR PI0907624A2 BR PI0907624 A BRPI0907624 A BR PI0907624A BR PI0907624 A BRPI0907624 A BR PI0907624A BR PI0907624 A2 BRPI0907624 A2 BR PI0907624A2
Authority
BR
Brazil
Prior art keywords
prevention
growth factor
heart disease
hepatocyte growth
disease treatment
Prior art date
Application number
BRPI0907624A
Other languages
English (en)
Inventor
Jong-Mook Kim
Sujeong Kim
Woong Hahn
Original Assignee
Viromed Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viromed Co Ltd filed Critical Viromed Co Ltd
Publication of BRPI0907624A2 publication Critical patent/BRPI0907624A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
BRPI0907624A 2008-01-25 2009-01-28 tratamento e prevenção de doenças cardíacas usando duas ou mais isoformas do fator de crescimento de hepatócito BRPI0907624A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2375608P 2008-01-25 2008-01-25
PCT/KR2009/000406 WO2009093880A2 (en) 2008-01-25 2009-01-28 Treatment and prevention of cardiac conditions using two or more isoforms of hepatocyte growth factor

Publications (1)

Publication Number Publication Date
BRPI0907624A2 true BRPI0907624A2 (pt) 2016-08-16

Family

ID=40901564

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0907624A BRPI0907624A2 (pt) 2008-01-25 2009-01-28 tratamento e prevenção de doenças cardíacas usando duas ou mais isoformas do fator de crescimento de hepatócito

Country Status (14)

Country Link
US (1) US20090202606A1 (pt)
EP (1) EP2252321B1 (pt)
JP (1) JP5563991B2 (pt)
KR (1) KR101325674B1 (pt)
CN (1) CN101925362A (pt)
AU (1) AU2009206869B2 (pt)
BR (1) BRPI0907624A2 (pt)
CA (1) CA2712078C (pt)
DK (1) DK2252321T3 (pt)
ES (1) ES2537971T3 (pt)
MX (1) MX2010007887A (pt)
PT (1) PT2252321E (pt)
RU (1) RU2448159C1 (pt)
WO (1) WO2009093880A2 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8409214B2 (en) * 2009-01-22 2013-04-02 Meditech Development Incorporated Portable regulated vacuum pump for medical procedures
KR100562824B1 (ko) * 2002-03-20 2006-03-23 주식회사 바이로메드 유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자
ES2556711T3 (es) * 2008-04-09 2016-01-19 Viromed Co., Ltd. Formulaciones liofilizadas de ADN para el aumento de la expresión del ADN plasmídico
AU2012333408B2 (en) * 2011-11-03 2016-05-26 Viromed Co., Ltd. Gene therapy for diabetic neuropathy using an HGF isoform
AU2014337870B2 (en) 2013-10-22 2019-11-28 Helixmith Co., Ltd. Composition for preventing or treating amyotrophic lateral sclerosis using two or more isoforms of hepatocyte growth factor
CN103519900A (zh) * 2013-10-24 2014-01-22 河南科技大学第一附属医院 一种心胸外科护肺膜
KR101567954B1 (ko) * 2013-11-25 2015-11-11 인하대학교 산학협력단 Hgf 단백질 또는 그 유전자를 포함하는 발기부전 예방 또는 치료용 조성물 및 그의 용도
CA2952121A1 (en) 2014-06-13 2015-12-17 Childrens' Medical Center Corporation Products and methods to isolate mitochondria
KR101756131B1 (ko) * 2014-09-26 2017-07-12 주식회사 바이로메드 간세포 성장인자 및 기질세포 유발인자1알파를 이용한 말초동맥질환의 예방 또는 치료용 조성물
US10435450B2 (en) 2015-01-21 2019-10-08 Centre National De La Recherche Scientifique MET receptor agonist proteins
DK4272834T3 (da) 2016-01-15 2025-12-15 Childrens Medical Ct Corp Terapeutisk anvendelse af mitokondrier og kombinerede mitokondrielle midler
WO2018167447A1 (en) * 2017-03-14 2018-09-20 University Of Sheffield Low dose aspirin (1-50 mg) together with antiplatelets such as ticagrelor of anticoagulants
CN109771642B (zh) 2017-11-13 2022-09-20 同济大学苏州研究院 c-MET激动型抗体及其用途
CA3106078A1 (en) 2018-07-17 2020-01-23 Junghun Lee Treatment of neuropathy with dna constructs expressing igf-1 isoforms
US11554179B2 (en) 2018-07-19 2023-01-17 Helixmith Co., Ltd Lyophilized pharmaceutical compositions for naked DNA gene therapy
EP3923963A4 (en) 2019-02-15 2022-11-23 Children's Medical Center Corporation TREATMENT OF HEART FAILURE

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ232813A (en) * 1989-03-10 1992-08-26 Snow Brand Milk Products Co Ltd Human fibroblast glycoprotein, cell differentiation, blood vessel endothelial cell growth factor, cellular immunology inforcing factor of 78 or 74 thousand daltons plus or minus two thousand daltons
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5693622A (en) * 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US6673776B1 (en) * 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
CA2022752C (en) * 1989-08-11 1998-07-07 Naomi Kitamura Hepatic parenchymal cell growth factor, gene encoding the same, process for producing the factor, and transformants producing the factor
US6706694B1 (en) * 1990-03-21 2004-03-16 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
JP2634323B2 (ja) * 1990-07-13 1997-07-23 雪印乳業株式会社 Ｔｃｆ‐▲ｉｉ▼のアミノ酸配列をコードするｄｎａを含むプラスミド，形質転換細胞及びこれを用いて生理活性物質を生産する方法
US5661133B1 (en) * 1991-11-12 1999-06-01 Univ Michigan Collateral blood vessel formation in cardiac muscle by injecting a dna sequence encoding an angiogenic protein
US6498144B1 (en) * 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
US5837676A (en) * 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US5652225A (en) * 1994-10-04 1997-07-29 St. Elizabeth's Medical Center Of Boston, Inc. Methods and products for nucleic acid delivery
US20030148968A1 (en) * 1995-02-28 2003-08-07 Hammond H. Kirk Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
EP0847757B1 (en) * 1995-08-29 2005-04-06 AnGes MG, Inc. Medicine comprising hgf gene
US5830879A (en) * 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor
US6121246A (en) * 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
JPH11246433A (ja) * 1998-03-03 1999-09-14 Sumitomo Pharmaceut Co Ltd 心筋梗塞治療剤
US20040228834A1 (en) * 1998-03-09 2004-11-18 Jeffrey Isner Compositions and methods for modulating vascularization
AU5065599A (en) * 1998-08-05 2000-02-28 Sumitomo Pharmaceuticals Company, Limited Preparations for the administration of hepatocyte growth factor
KR20000046969A (ko) 1998-12-31 2000-07-25 이선경 이종 유전자 유래의 유전자 발현 조절요소를 포함하는 강력한전사 활성을 가진 진핵세포 발현벡더
ES2313907T3 (es) * 1999-10-29 2009-03-16 Anges Mg, Inc. Terapia genica para la isquemia diabetica.
DE60134021D1 (de) * 2000-06-27 2008-06-26 Anges Mg Inc Pharmazeutische zubereitungen zur angiogenese-therapie
EP1361896A2 (en) * 2001-01-23 2003-11-19 Boston Scientific Corporation Localized myocardial injection method for treating ischemic myocardium
EP1234583A1 (en) * 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-conjugates of HGF-NK4
KR100562824B1 (ko) * 2002-03-20 2006-03-23 주식회사 바이로메드 유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자
WO2006121532A2 (en) * 2005-03-31 2006-11-16 Mytogen, Inc. Treatment for heart disease
US20070212390A1 (en) * 2005-09-22 2007-09-13 Ludwig Institute For Cancer Research Protease-resistant forms of VEGF-D, method of making and method of use
CA2628928A1 (en) * 2005-11-10 2007-05-24 Receptor Biologix, Inc. Hepatocyte growth factor intron fusion proteins
ES2556711T3 (es) * 2008-04-09 2016-01-19 Viromed Co., Ltd. Formulaciones liofilizadas de ADN para el aumento de la expresión del ADN plasmídico

Also Published As

Publication number Publication date
AU2009206869A1 (en) 2009-07-30
DK2252321T3 (en) 2015-05-26
CN101925362A (zh) 2010-12-22
JP2011510069A (ja) 2011-03-31
EP2252321A4 (en) 2012-09-05
RU2448159C1 (ru) 2012-04-20
CA2712078C (en) 2015-02-24
WO2009093880A3 (en) 2009-10-29
EP2252321A2 (en) 2010-11-24
KR101325674B1 (ko) 2013-11-06
RU2010135532A (ru) 2012-02-27
EP2252321B1 (en) 2015-04-29
WO2009093880A2 (en) 2009-07-30
MX2010007887A (es) 2010-08-10
AU2009206869B2 (en) 2012-04-19
ES2537971T3 (es) 2015-06-16
KR20100126316A (ko) 2010-12-01
US20090202606A1 (en) 2009-08-13
PT2252321E (pt) 2015-07-07
CA2712078A1 (en) 2009-07-30
JP5563991B2 (ja) 2014-07-30

Similar Documents

Publication Publication Date Title
BRPI0907624A2 (pt) tratamento e prevenção de doenças cardíacas usando duas ou mais isoformas do fator de crescimento de hepatócito
FIC20240036I1 (fi) Geeniterapia, joka ilmentää ihmisen hyytymistekijä IX:n muunnosta R338L
FR2921499B1 (fr) Structure orientable de type catheter ou endoscope
IL241985A0 (en) Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents
HUS1600048I1 (hu) Készítmény Fabry-kór kezelésére
IT1391555B1 (it) Apparato trattamento extracorporeo sangue
EP2278999C0 (en) EAR PREPARATIONS FOR THE TREATMENT OF EAR DISEASES AND CONDITIONS
IL209336B (en) Compositions for treating hyperproliferative diseases and uses thereof
HUE061548T2 (hu) Komplementtel összefüggõ rendellenességek kezelésére szolgáló eljárások és készítmények
HRP20190031T1 (hr) Sintetski triterpenoidi i postupci njihove upotrebe u liječenju bolesti
BRPI1012116A2 (pt) composição farmacêutica para o tratamento de doenças cardíacas
BR112012002124A2 (pt) tratamento da doença de crohn com laquinimode.
DK2245199T3 (da) Anvendelse af mikrovesikler i diagnosticering, prognosticering og behandling af medicinske sygdomme og tilstande
BRPI0911004A2 (pt) Artigo antimicrobiano, líquido de tratamento e métodos de preparação dos mesmos
DK2222272T3 (da) Behandling af luftvejssygdom
BRPI0815551A2 (pt) Tratamento através de hucbc de doença beta-amiloide
PT2099321T (pt) Composições de leite humano e métodos de fabrico e utilização das mesmas
BRPI1008517A2 (pt) direcionamento duplo de mir-208 e mir-499 no tratamento de doenças cardíacas.
PL2307000T3 (pl) Połączenie pilokarpiny i metimazolu do leczenia choroby Charcota-Mariegotootha i pokrewnych zaburzeń
IL216967B (en) The history of 17-hydroxy-17-pentafluoroethyl-astra-9,4 (10)-diene-11-aryl and their use for the treatment of diseases
EP2091480A4 (en) SYSTEM FOR THE TREATMENT OF HEART TISSUE
SI2234631T1 (sl) Spojine in postopki za zdravljenje ĺ˝ilne bolezni
FR2934052B1 (fr) Dosage de l'activite du facteur tissulaire circulant
FI20095600L (fi) Koostumus ihosairauksien hoitoa varten
BRPI0820449A2 (pt) Conjunto de implante médico interfaceado

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B25D Requested change of name of applicant approved

Owner name: HELIXMITH CO., LTD (KR)

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25G Requested change of headquarter approved

Owner name: HELIXMITH CO., LTD (KR)

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]